Nkarta Inc. (NKTX)
NASDAQ: NKTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 11:18 AM ET
NKTX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $157.57M
- EPS (TTM)
- -$1.58
- Dividend yield
- None
- 52-week range
- 1.70 – 3.72
- Day range
- 2.16 – 2.26
- Volume / Avg
- 199.79K / 617.86K
- Beta
- —
- Shares outstanding
- 71.62M
- Next earnings
- Nov 10, 2026
52-week range
NKTX stock today
Shares of Nkarta (NKTX) are trading lower on Oct 8 at $2.20, a drop of 3.08% or $0.07 per share, versus the S&P 500's 0.38% decline. Shares are 40.9% below their 52-week high of $3.72, set on Jul 9, 2026 and 29.4% above the 52-week low of $1.70, in the middle of the past year's range. NKTX is up 22.7% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 10.2%.
Nkarta has posted a net loss over the last twelve months (EPS of -$1.58), so its P/E ratio is not meaningful. Nkarta's next earnings report is expected on Nov 10, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Nkarta
Company profileNkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Paul J. Hastings
- Headquarters
- South San Francisco, CA
- Employees
- 106
- IPO year
- 2020
- Website
- nkartatx.com
Analyst forecast
ForecastConsensus (7 analysts)
strong_buy
Avg. price target
$10.83+392.27%
- Strong buy 1
- Buy 6
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 10, 2026
Nkarta peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ORGOOrganogenesis Holdings Inc. Class A | 1.27 | -4.17% | $162.77M | vs NKTX |
| EMISEmmis Acquisition Corp. Class A | 10.27 | 0.00% | $162.02M | vs NKTX |
| MSLESatellos Bioscience Inc. | 7.63 | -0.07% | $161.78M | vs NKTX |
| DERMJourney Medical Corporation | 6.02 | +1.20% | $169.95M | vs NKTX |
| ANTXAN2 Therapeutics Inc. | 4.53 | -6.60% | $170.95M | vs NKTX |
| PEPGPepGen Inc. | 2.31 | -3.96% | $159.44M | vs NKTX |
| CNTNCanton Strategic Holdings Inc. | 2.18 | -3.77% | $173.31M | vs NKTX |
| ORMPOramed Pharmaceuticals Inc. | 4.18 | -4.34% | $173.88M | vs NKTX |
Indexes, lists and sector
Nkarta stock FAQ
What is Nkarta's stock price today?
NKTX last traded at $2.20 as of Oct 8, 11:18 AM EDT, down 3.08% on the day. Prices are delayed at least 15 minutes.
When is Nkarta's next earnings date?
Nkarta is expected to report earnings on Tuesday, November 10, 2026.
Who is Nkarta's CEO?
Mr. Paul J. Hastings is the chief executive officer of Nkarta Inc., which has about 106 employees.
What is the NKTX 52-week high?
The 52-week high for NKTX is $3.72 and the 52-week low is $1.70. The stock is currently 40.9% below its high.